[2] PATTERSON T F,THOMPSON G R,DENNING D W,et al. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Diseases Society of America[J].
Clin Infect Dis,2016,63( 4) : e1 - e60.
[3] BARRETO J N,BEACH C L,WOLF R C,et al. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole[J]. Am J Hematol,2013,88( 4) : 283 - 288.
[5] CONSIGNY S,DHEDIN N,DATRY A,et al. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient[J]. Clin Infect Dis,2003,37( 2) : 311 - 313.
[6] KLONT R R,EGGINK C A,RIJS A J,et al. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole[J]. Clin Infect Dis,2005,40( 12) : e110 - e112.
[9] JIN H,WANG T,FALCIO B A,et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis[J]. J Antimicrob Chemother,2016,71(
7) : 1772 - 1785.
[10] JAGER N G,VAN HEST R M,LIPMAN J,et al. Therapeutic drug monitoring of anti-infective agents in critically ill patients[J]. Expert Rev Clin Pharmacol,2016,9 ( 7 ) :961 - 979.
[11] KANG H M,LEE H J,CHO E Y,et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections[J]. Pediatr Hematol Oncol,2015,32(8) : 557 - 567.
[12] HAMADA Y,TOKIMATSU I,MIKAMO H,et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J]. J Infect Chemother,2013,19( 3) : 381 - 392.
[13] ASHBEE H R,BARNES R A,JOHNSON E M,et al. Therapeutic drug monitoring ( TDM) of antifungal agents: guidelines from the British Society for Medical Mycology[J]. J Antimicrob Chemother,2014,69( 5) : 1162 - 1176.
[15] PASCUAL A,CALANDRA T,BOLAY S,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J]. Clin Infect Dis,2008,46( 2) : 201 - 211.
[16] MITSANI D,NGUYEN M H,SHIELDS R K,et al. Prospective,observational
study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs,efficacy,and toxicity[J]. Antimicrob Agents Chemother,2012,56( 5) : 2371 - 2377.
[17] MATSUMOTO K,ABEMATSU K,SHIGEMI A,et al. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data[J]. J Chemother,2016,28( 3) : 198 - 202.
[18] BODRO M,SABE N,GOMILA A,et al. Risk factors,clinical characteristics,and outcomes of invasive fungal infections in solid organ transplant recipients[J]. Transplant Proc,2012,44( 9) : 2682 - 2685.
[19] LEMPERS V J,MARTIAL L C,SCHREUDER M F,et al. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice[J]. Curr Opin Pharmacol,2015,24: 38 - 44.
[20] SAAD A H,DEPESTEL D D,CARVER P L. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants[J]. Pharmacotherapy,2006,26( 12) : 1730 - 1744.
[21] DRESSER G K,SPENCE J D,BAILEY D G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition[J]. Clin pharmacokinet,2000,38( 1) : 41 - 57.
[22] DOLTON M J,RAY J E,CHEN S C,et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring[J]. Antimicrob Agents Chemother,2012,56 ( 9 ) :4793 - 4799.
[23] PARK W B,KIM N H,KIM K H,et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial[J]. Clin Infect Dis,2012,55( 8) : 1080 - 1087.